Citeline：2022年度临床试验概述白皮书（中译版）（20页）.pdf

1、2022 Clinical Trials RoundupOctober 2023White PaperHeidi ChenAssociate Director,Research&Commercial Services2October 2023 Copyright 2023 Citeline,a Norstella company.(Unauthorized photocopying prohibited).2022 Clinical Trials Roundup1.Citeline(2022)2021 Clinical Trials Roundup:Clinical Trials Resili

2、ence After Pandemic Disruptions.2.The data snapshot dates for full-year activity are June 26,2023;June 23,2022;June 14,2021;June 12,2020;June 5,2019;June 6,2018;and July 6,2017.Due to delays in reporting of trial activity,counts for prior years will have likely grown since the original data snapshot

3、 date.Last year we remarked on the resilience and return of clinical trial momentum post-pandemic,where we saw a 6%growth of total trials(22%excluding COVID-19 trials)in 2021.1 One year later,the roller coaster resumes as the healthcare industry continues to be influenced by the global economy and p

4、olitical climate.Big headline events the Inflation Reduction Act,the ongoing Russo-Ukrainian war,harsh funding cuts and divestments in the biopharma sector,and stalled economic growth in China are just a few headwinds the healthcare industry braved in 2022.As the world picks up the pace to rebuild m

5、omentum and put the pandemic behind it,navigating through the evolving regulatory guidance and market dynamics calls for endurance and perseverance.As with each edition of our Clinical Trials Roundup,we focus on an overview of the Phase IIII clinical trials that initiated in the prior calendar year(

6、2022)across all therapeutic areas comprehensively covered by Trialtrove,as well as in-depth analyses into the key diseases,players,and geographies that impact the pharmaceutical industry.We will also look at any lingering effect of the pandemic,recovery,and challenges of adapting to the new equilibr